03.03.2020 – 11:14
Press Release: Dr. Stephan Eder is appointed as Executive Vice President of STADA Russia/CIS
Dr. Stephan Eder is appointed as Executive Vice President of STADA Russia/CIS
- Stephan Eder decides to join STADA mid-year as Executive Vice President of Russia-CIS, the second-largest business within the STADA Group - Stephan Eder has more than 15 years of experience in the health care industry. He has decided to join STADA from Sandoz, where he most recently held the position of CEO Hexal and Country Head Sandoz Germany. - STADA CEO Peter Goldschmidt: “I am delighted that we will have with Stephan joining a great addition to our Executive Team. Stephan is an inspiring growth leader with a proven success record in Russia, Germany and the UK.“
Bad Vilbel, March 3, 2020 – Mid-year, Dr. Stephan Eder will strengthen the global STADA Executive Committee as Executive Vice President Russia/CIS. In this role, he will oversee all operations in STADA Russia as well as in the CIS countries. Russia is with more than 3000 employees the second largest business within the global STADA Group.
“With the acquisition of Takeda’s Russian portfolio, STADA becomes number one in Russia’s OTC market and the second-largest employer in the pharmaceutical industry,” points out STADA CEO Peter Goldschmidt. “I am delighted that we will have with Stephan joining a great addition to our Executive Team. Stephan is an inspiring growth leader with a proven success record in Russia, Germany and the UK.“
Stephan Eder joins STADA from Sandoz, where he most recently served as CEO Hexal and Country Head Sandoz Germany from mid-2017 onwards. With a clear vision, he led the German Sandoz team and business through a strategic transformation to drive increased customer focus, resulting in strong sales and profit growth as well as an expansion of market leadership in Germany.
Having started his career at McKinsey, Austrian national Stephan Eder was co-founder and CFO of the start up drug-discovery company 55pharma before joining Sandoz’ parent group, Novartis, in 2007. After working in corporate strategy roles at Novartis, he subsequently led Sandoz’ portfolio management, business development and licensing function in Central and Eastern Europe before he was responsible for the Russian OTC operation from mid-2010 until end 2013. During this period under his leadership, the business almost doubled in size and strongly outgrew the Russian OTC market. Subsequently until mid-2017, Stephan Eder headed Sandoz’ operations in the UK and Ireland as General Manager, successfully growing the business and driving sustainable results in a highly volatile market.
In his role heading STADA’s operations in Russia and CIS, Stephan will be responsible for a strengthened and growing commercial organization as well as for business development and all production sites. STADA remains highly committed to be an industry leader in Russia, having invested more than EUR 1 billion in the country in recent years, making the German group the largest foreign investor in the Russian pharmaceutical industry.
At STADA, Stephan Eder will be a crucial part of the company’s growth journey to ensure that STADA lives up to its vision to be the partner of choice in generics as well as in consumer healthcare and to outperform the industry in terms of growth and profitability.
“I am very excited to join STADA, a company with a clear vision and an inspiring growth journey. I look very much forward to returning to Russia and supporting our local team to accelerate a strong sales and profit growth trajectory,” comments Stephan Eder.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: email@example.com
Or visit us on the Internet at www.stada.com/press
Additional information for capital market participants:
STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: firstname.lastname@example.org
Or visit us on the Internet at www.stada.com/investor-relations